Abstract
Using Fmoc to protect the amino group, Fmoc-doxorubicin is conjugated through the 14-hydroxy group to the amino group of melanotransferrin p97 by spacer arms such as succinate and glutarate. The Fmoc group is then removed under basic conditions, which affords doxorubicin-p97 conjugates. The resulting bioconjugates are potential agents for treating brain tumors.
Acknowledgments
We are grateful to Dr. Pascale Tiger, Dr. Malcolm Kennard, and Dr. Gavin Arthur for their helpful discussions.